Related Experiment Video

Updated: Apr 27, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.9K

Transformer 2β (Tra2β/SFRS10) positively regulates the progression of NSCLC via promoting cell proliferation

Lili Ji1, Tingting Ni, Yanbo Shen

  • 1Department of Pathology, Medical College, Nantong University, Nantong, 226001, Jiangsu, China.

Journal of Molecular Histology
|June 22, 2014
PubMed

Insights

Transformer 2β (Tra2β) promotes non-small cell lung cancer (NSCLC) growth and is linked to poor prognosis. Targeting Tra2β may offer a new therapeutic strategy for NSCLC patients.

Area of Science:

  • Molecular Biology
  • Oncology
  • RNA Biology

Background:

  • Transformer 2β (Tra2β) is an RNA-binding protein implicated in alternative splicing.
  • Dysregulation of Tra2β is observed in various cancers.
  • The specific role of Tra2β in non-small cell lung cancer (NSCLC) remains unclear.

Purpose of the Study:

  • To investigate the role of Transformer 2β (Tra2β) in the development and progression of non-small cell lung cancer (NSCLC).
  • To evaluate Tra2β as a potential prognostic marker and therapeutic target in NSCLC.

Main Methods:

  • Western blot and immunohistochemistry to assess Tra2β expression in NSCLC tissues.
  • Correlation analysis (Spearman) to link Tra2β expression with clinicopathological features and Ki67.
  • Kaplan-Meier and multivariate analyses for prognostic evaluation.
  • Cellular assays (proliferation, apoptosis, Western blot, flow cytometry, CCK-8, TUNEL) to determine Tra2β's functional impact on NSCLC cells.

Main Results:

  • Tra2β expression is significantly upregulated in NSCLC tissues compared to adjacent non-tumor tissues.
  • High Tra2β expression correlates with poor histological differentiation, advanced clinical stage, and increased proliferation (Ki67).
  • Elevated Tra2β predicts poor overall survival and serves as an independent prognostic indicator.
  • Tra2β promotes NSCLC cell proliferation and inhibits apoptosis; its knockdown reduces proliferation and induces apoptosis.

Conclusions:

  • Transformer 2β (Tra2β) plays a crucial role in non-small cell lung cancer (NSCLC) tumorigenesis.
  • Tra2β is associated with aggressive tumor features and predicts poor prognosis in NSCLC patients.
  • Tra2β represents a potential therapeutic target for NSCLC treatment.

More Related Videos

The Soft Agar Colony Formation Assay08:01

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

112.5K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

6.8K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
3.7K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.9K